Join4ATMP Partner Fondazione Telethon Contributes to EMA-Focused Dialogue on ATMP Development Platform Approach

Last November, Fondazione Telethon proudly participated in the fourth listen-and-learn focus group meeting organised by the European Medicines Agency (EMA) Quality Innovation Group. The meeting, held as part of an ongoing initiative to advance innovation in medicine, focused on exploring a platform approach for the development of Advanced Therapy Medicinal Products (ATMPs).

Representing both Join4ATMP and the Join4ATMP-T2EVOLVE collaboration, Fondazione Telethon contributed actively to discussions and strategic alignment efforts aimed at streamlining ATMP development. The presentation on the platform approach, delivered by Sean Russell, outlined key opportunities to harmonise quality, regulatory, and scientific standards for innovative therapies across Europe.

Fondazione Telethon's contribution is highlighted in Section 3.6 of the meeting’s report, which is publicly available on the EMA website.

This engagement reflects Fondazione Telethon’s ongoing commitment to accelerating the development and accessibility of cutting-edge therapies for rare and genetic diseases, in close partnership with leading European research and regulatory bodies.